Clinical Trial Update: Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing jaktinib to hydroxyurea in intermediate-2 or high-risk myelofibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Hydroxycarbamide (hydroxycarbamide)
• Jaktinib (jaktinib)

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: Myelofibrosis | Phase 3 | Status: COMPLETED